(S)-1-(2-methoxyphenyl)-N-methylpropan-2-amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-1-(2-methoxyphenyl)-N-methylpropan-2-amine
• 英文别名: (2S)-1-(2-methoxyphenyl)-N-methylpropan-2-amine
• 化学式: C₁₁H₁₇NO
• 分子量: 179.262
• InChiKey: OEHAYUOVELTAPG-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

ADMET

代谢

Ac1ocg1j 已知的人类代谢物包括 4-甲氧基-3-[2-(甲基氨基)丙基]苯酚和 O-去甲基甲氧基苯胺。

Ac1ocg1j has known human metabolites that include 4-Methoxy-3-[2-(methylamino)propyl]phenol and O-Desmethylmethoxyphenamine.

来源:NORMAN Suspect List Exchange

反应信息

• 作为反应物：
  描述：

  (S)-1-(2-methoxyphenyl)-N-methylpropan-2-amine 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 以70%的产率得到(S)-2-(2-methylaminopropyl)phenol
  参考文献：
  名称：

  Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response

  摘要：

  We hypothesized that an anti-METH mAb could be used in combination with a METH-conjugate vaccine (MCV) to safely improve the overall quality and magnitude of the anti-METH immune response. The benefits would include immediate onset of action (from the mAb), timely increases in the immune responses (from the combined therapy) and duration of antibody response that could last for months (from the MCV). A novel METH-like hapten (METH-SSOO9) was synthesized and then conjugated to immunocyanin monomers of keyhole limpet hemocyanin (ICKLH) to create the MCV ICKLH-SOO9. The vaccine, in combination with previously discovered anti-METH mAb7F9, was then tested in rats for safety and potential efficacy. The combination antibody therapy allowed safe achievement of an early high anti-METH antibody response, which persisted throughout the study. Indeed, even after 4 months the METH vaccine antibodies still had the capacity to significantly reduce METH brain concentrations resulting from a 0.56 mg/kg METH dose.

  DOI：

  10.1021/acs.jmedchem.5b00220
• 作为产物：
  描述：

  邻甲氧基苯丙酮 在 甲醇 、 L-酒石酸 、 铂 作用下， 生成 (S)-1-(2-methoxyphenyl)-N-methylpropan-2-amine
  参考文献：
  名称：

  Physiologically Active Secondary Amines. β-(o-Methoxyphenyl)-isopropyl-N-methylamine and Related Compounds

  摘要：

  DOI：

  10.1021/ja01100a043

文献信息

• METHOD OF ENANTIOSELECTIVE ADDITION TO IMINES
  申请人：UANG Biing-Jiun

  公开号：US20120004441A1

  公开（公告）日：2012-01-05

  The present invention relates to a method of enantioselective addition to imines, including: reacting R 3 CH═NY with R 4 ZnR 5 in the presence of a compound represented by the following formula (I), in which Y, R 1 , R 2 , R 3 , R 4 and R 5 are defined the same as the specification. Accordingly, the present invention can prepare secondary amines in high yields and enantiomeric excess by the above-mentioned method.

  本发明涉及一种对亚胺进行对映选择性加成的方法，包括：在以下式(I)所代表的化合物存在下，将R3CH═NY与R4ZnR5反应，其中Y、R1、R2、R3、R4和R5的定义与规范相同。因此，本发明可以通过上述方法高产率和对映过量地制备二级胺。
• US8461371B2
  申请人：——

  公开号：US8461371B2

  公开（公告）日：2013-06-11
• US9193743B2
  申请人：——

  公开号：US9193743B2

  公开（公告）日：2015-11-24
• Physiologically Active Secondary Amines. β-(o-Methoxyphenyl)-isopropyl-N-methylamine and Related Compounds
  作者：R. V. Heinzelman

  DOI：10.1021/ja01100a043

  日期：1953.2
• Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response
  作者：Michael D. Hambuchen、F. Ivy Carroll、Daniela Rüedi-Bettschen、Howard P. Hendrickson、Leah J. Hennings、Bruce E. Blough、Lawrence E. Brieaddy、Ramakrishna R. Pidaparthi、S. Michael Owens

  DOI：10.1021/acs.jmedchem.5b00220

  日期：2015.6.11

  We hypothesized that an anti-METH mAb could be used in combination with a METH-conjugate vaccine (MCV) to safely improve the overall quality and magnitude of the anti-METH immune response. The benefits would include immediate onset of action (from the mAb), timely increases in the immune responses (from the combined therapy) and duration of antibody response that could last for months (from the MCV). A novel METH-like hapten (METH-SSOO9) was synthesized and then conjugated to immunocyanin monomers of keyhole limpet hemocyanin (ICKLH) to create the MCV ICKLH-SOO9. The vaccine, in combination with previously discovered anti-METH mAb7F9, was then tested in rats for safety and potential efficacy. The combination antibody therapy allowed safe achievement of an early high anti-METH antibody response, which persisted throughout the study. Indeed, even after 4 months the METH vaccine antibodies still had the capacity to significantly reduce METH brain concentrations resulting from a 0.56 mg/kg METH dose.